Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia.

Lu Y, Li Y, Chai X, Kang Q, Zhao P, Xiong J, Wang J.

Gene. 2017 Apr 5;607:41-46. doi: 10.1016/j.gene.2017.01.004. Epub 2017 Jan 6.

PMID:
28069548
2.

The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.

Wang H, Li Q, Tang S, Li M, Feng A, Qin L, Liu Z, Wang X.

Hematology. 2017 May;22(4):208-216. doi: 10.1080/10245332.2016.1258152. Epub 2016 Nov 22. Erratum in: Hematology. 2018 Dec;23(10):864.

PMID:
27875938
3.

A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.

Guo G, Kang Q, Zhu X, Chen Q, Wang X, Chen Y, Ouyang J, Zhang L, Tan H, Chen R, Huang S, Chen JL.

Oncogene. 2015 Apr 2;34(14):1768-79. doi: 10.1038/onc.2014.131. Epub 2014 May 19.

PMID:
24837367
4.

ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells.

Wu J, Wei B, Wang Q, Ding Y, Deng Z, Lu X, Li Y.

Cell Biochem Biophys. 2016 Jun;74(2):277-83. doi: 10.1007/s12013-016-0725-x. Epub 2016 Feb 24.

PMID:
26912059
5.
6.

HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas.

Zhu Y, Zhang X, Qi L, Cai Y, Yang P, Xuan G, Jiang Y.

Oncotarget. 2016 Mar 22;7(12):14429-40. doi: 10.18632/oncotarget.7418.

7.

The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia.

Chen Y, Wang T, Du J, Li Y, Wang X, Zhou Y, Yu X, Fan W, Zhu Q, Tong X, Wang Y.

Cell Physiol Biochem. 2018;47(3):981-993. doi: 10.1159/000490142. Epub 2018 May 24.

8.

Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.

Wang WZ, Pu QH, Lin XH, Liu MY, Wu LR, Wu QQ, Chen YH, Liao FF, Zhu JY, Jin XB.

Leuk Res. 2015 Oct;39(10):1117-24. doi: 10.1016/j.leukres.2015.07.008. Epub 2015 Jul 21.

PMID:
26248946
9.

Long non-coding RNA HULC promotes proliferation, migration and invasion of pancreatic cancer cells by down-regulating microRNA-15a.

Feng H, Wei B, Zhang Y.

Int J Biol Macromol. 2019 Apr 1;126:891-898. doi: 10.1016/j.ijbiomac.2018.12.238. Epub 2018 Dec 26.

PMID:
30593805
10.

Pro-Angiogenic Role of LncRNA HULC in Microvascular Endothelial Cells via Sequestrating miR-124.

Yin D, Li Y, Fu C, Feng Y.

Cell Physiol Biochem. 2018;50(6):2188-2202. doi: 10.1159/000495060. Epub 2018 Nov 9.

11.

Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.

Chen Y, Zhou Q, Zhang L, Zhong Y, Fan G, Zhang Z, Wang R, Jin M, Qiu Y, Kong D.

Oncotarget. 2017 Apr 25;8(17):28906-28921. doi: 10.18632/oncotarget.15957.

12.

Knockdown of lncRNA CCAT2 inhibits endometrial cancer cells growth and metastasis via sponging miR-216b.

Xie P, Cao H, Li Y, Wang J, Cui Z.

Cancer Biomark. 2017 Dec 12;21(1):123-133. doi: 10.3233/CBM-170388.

PMID:
29036788
13.

Long noncoding RNA MEG3 inhibits proliferation of chronic myeloid leukemia cells by sponging microRNA21.

Li Z, Yang L, Liu X, Nie Z, Luo J.

Biomed Pharmacother. 2018 Aug;104:181-192. doi: 10.1016/j.biopha.2018.05.047. Epub 2018 May 15.

PMID:
29772439
14.

HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.

Sugimoto Y, Nakamura S, Okinaka K, Hirano I, Ono T, Shigeno K, Shinjo K, Ohnishi K.

Leuk Res. 2008 Jun;32(6):962-71. doi: 10.1016/j.leukres.2007.11.034. Epub 2008 Jan 10.

PMID:
18190961
15.

The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells.

Zeng C, Liu S, Lu S, Yu X, Lai J, Wu Y, Chen S, Wang L, Yu Z, Luo G, Li Y.

Mol Cancer. 2018 Aug 28;17(1):130. doi: 10.1186/s12943-018-0884-z.

16.

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R, Galinsky I, Fox E, Kung AL, Griffin JD.

Blood. 2008 Apr 1;111(7):3723-34. doi: 10.1182/blood-2007-09-114454. Epub 2008 Jan 9.

17.

MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro.

Jiang MJ, Dai JJ, Gu DN, Huang Q, Tian L.

Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):372-378. doi: 10.1016/j.bbrc.2017.10.001. Epub 2017 Oct 3.

PMID:
28986256
18.

Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.

de Cássia Viu Carrara R, Fontes AM, Abraham KJ, Orellana MD, Haddad SK, Palma PVB, Panepucci RA, Zago MA, Covas DT.

Clin Transl Oncol. 2018 Apr;20(4):542-549. doi: 10.1007/s12094-017-1751-x. Epub 2017 Sep 13.

PMID:
28905209
19.

LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.

Wen F, Cao YX, Luo ZY, Liao P, Lu ZW.

Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):1-8. doi: 10.1016/j.bbrc.2018.09.034. Epub 2018 Oct 23.

PMID:
30366670
20.

Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.

Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R.

Cancer Biol Ther. 2012 Nov;13(13):1244-54. doi: 10.4161/cbt.21460. Epub 2012 Aug 16.

Supplemental Content

Support Center